Affecting approximately 27% of adult shift workers, shift work disorder arises when required work schedules overlap with natural sleep timing for at least three months, causing excessive sleepiness and insomnia due to circadian misalignment.
Following a systematic review and meta-analysis, the American Academy of Sleep Medicine (AASM) published a new clinical practice guideline in the Journal of Clinical Sleep Medicine. The publication establishes evidence-based recommendations for managing shift work disorder in adults through behavioral, pharmacologic, and circadian-based interventions.
“There is no one-size-fits-all solution for shift work disorder,” Kenneth P Wright Jr told Sleep Review, noting that patients have different schedules and symptoms.
At the University of Colorado Boulder, Wright functions as a professor of distinction in integrative physiology, directs the Sleep and Chronobiology Laboratory, and holds a doctorate in behavioral neuroscience and psychology. The new guideline builds upon previous practice parameters by applying a systematic, evidence-graded approach to evaluate treatment benefits and harms.
Plain English Medical Intelligence
- Circadian Misalignment: A disruption occurring when an individual’s internal biological clock conflicts with their required work and sleep timing.
- Armodafinil and Modafinil: Wake-promoting medications suggested by the AASM to improve alertness during night shifts, backed by moderate-certainty evidence.
- Cognitive Behavioral Therapy for Insomnia (CBT-I): A recommended behavioral intervention used to address difficulty initiating or maintaining sleep in relation to work schedules.
Use Armodafinil or Modafinil to Improve Alertness
For adults experiencing excessive sleepiness during night shifts, the guideline suggests using armodafinil or modafinil to improve alertness. The guideline also suggests considering caffeine, bright light exposure, strategic naps, and adjustments to meal timings. However, the evidence supporting these additional approaches is of low certainty, and their effectiveness varies depending on individual circumstances.
Not involved in the research, Dr. Derk Krieger, PhD, who serves as a consultant neurologist and professor of neurology at Re:Cognition Health, pointed out to Medical News Today that armodafinil and modafinil represent some of the more strongly backed pharmaceutical choices for addressing excessive sleepiness.
“They can improve alertness and may help people function during night shifts,” Krieger told Medical News Today. He added that these drugs do not correct the underlying disruption to the body clock and cannot replace adequate sleep.
For patients facing difficulty initiating or maintaining sleep, the guideline suggests cognitive behavioral therapy for insomnia, melatonin, melatonin receptor agonists, and certain hypnotic agents. Conversely, the AASM suggests against using some hypnotic agents with unfavorable risk-benefit profiles, including select benzodiazepines.
| Intervention Category | Recommended Strategies | Evidence Certainty |
|---|---|---|
| Excessive Sleepiness | Armodafinil, modafinil, caffeine, strategic naps, bright light exposure, meal timing | Moderate for modafinil and armodafinil; low for auxiliary methods |
| Insomnia Symptoms | CBT-I, melatonin, melatonin receptor agonists | Varies by modality |
| Circadian Misadaptation | Timed bright light, consistent sleep schedules, meal timing | Low to moderate |
Targeting Circadian Realignment
To address circadian misalignment, the guideline suggests timed bright light exposure, maintaining consistent sleep schedules when feasible, and utilizing light-filtering strategies during the commute home. These interventions aim to help bridge the gap between biological sleep timing and professional demands.
The AASM commissioned a task force of experts in sleep and circadian medicine to systematically review published literature. The resulting guidance emphasizes that evidence quality varies across treatments, highlighting the necessity of shared decision-making between clinicians and patients.
Formal support for the guideline came from the Sleep Health Foundation, Project Sleep, Sleep Charity, the Nurse Practitioner Association of Canada, the Society of Behavioral Sleep Medicine, and the Australasian Sleep Association.
Consult a Physician for Persistent Sleep Disturbance
Patients should avoid interventions carrying unfavorable risk-benefit profiles, such as certain benzodiazepine hypnotic agents flagged by the AASM. Because wake-promoting agents like modafinil and armodafinil do not correct underlying circadian disruption, individuals experiencing persistent sleep disturbance lasting three months or longer should consult a qualified physician or sleep medicine specialist for a tailored evaluation.
Disclaimer: This article is published for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment.
